Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Tolcapone-related liver dysfunction - Implications for use in Parkinson's disease therapy
Publication

Publications

Tolcapone-related liver dysfunction - Implications for use in Parkinson's disease therapy

Title
Tolcapone-related liver dysfunction - Implications for use in Parkinson's disease therapy
Type
Article in International Scientific Journal
Year
2003
Authors
Borges, Nuno
(Author)
FCNAUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Journal
Title: Drug SafetyImported from Authenticus Search for Journal Publications
Vol. 26 No. 11
Pages: 743-747
ISSN: 0114-5916
Publisher: Springer Nature
Scientific classification
FOS: Medical and Health sciences > Health sciences
CORDIS: Health sciences
Other information
Authenticus ID: P-000-JGW
Abstract (EN): Levodopa is the cornerstone of idiopathic Parkinson's disease (PD) treatment. However, after long-term use of levodopa, a significant percentage of patients experience motor fluctuations, which worsen their quality of life. Catechol-O-methyltransferase (COMT) inhibitors reduce levodopa metabolism and enhance the respective plasma levels, resulting in improvements in symptoms and overall quality of life. Tolcapone was the first drug of this class to be marketed, but was withdrawn in the European Union due to its implication in the deaths of three PD patients due to hepatic failure. Three deaths from fulminant hepatic failure in 40 000 patient-years is a number that is 10-100 times higher than the expected incidence in the general population and, according to the manufacturer's own information, the number is probably underestimated due to under-reporting of cases. In the US, tolcapone was not withdrawn, but restrictive liver enzyme monitoring measures were issued by authorities, which severely limited its use. No further deaths from hepatic failure were reported since these measures were implemented. The mechanisms by which tolcapone may induce liver toxicity are still under debate. It was thought that mitochondrial uncoupling of oxidative phosphorylation by tolcapone, and consequent impairment of energy production by hepatocytes, could be responsible for the observed effects. Some experts consider that the restrictive guidelines issued in the US regarding tolcapone use may be loosened with no consequential reductions in safety. It was suggested that ongoing clinical information about safety should be considered and periodical revisions of the restrictions made accordingly. The identification of the molecular and biochemical basis of tolcapone hepatotoxicity, when completed, should also provide important indications for the clinical use of this drug. In conclusion, appropriate monitoring of liver function can ensure adequate safety in PD patients receiving tolcapone, who can therefore benefit from the symptomatic improvements obtained with this drug.
Language: English
Type (Professor's evaluation): Scientific
Contact: nunoborgesfcna.up.pt
No. of pages: 5
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same authors

Protective effect of Physical Activity on Dissatisfaction with Body Image in Children: A Cross-Sectional Study (2011)
Poster in a National Conference
Gaspar, Marisa; Amaral, Teresa; Oliveira, Bruno; Borges, Nuno
Ocorrência de cafestol e caveol em amostras de café (2011)
Poster in a National Conference
Silva, José Avelino ; Fard, Marzieh Moeen ; Borges, Nuno ; Santos, Alejandro ; Alves, Arminda
Dietary treatment in phenylketonuria does not lead to increased risk of obesity or metabolic syndrome (2013)
Poster in a National Conference
Rocha, Júlio; Spronsen, F.; Almeida, M.; Soares, G.; Quelhas, D.; Ramos, Elisabete; Guimarães, João; Borges, Nuno
Overweight and obesity in phenylketonuric patients from the north of Portugal. (2011)
Poster in an International Conference
Rocha, Júlio César; Guimarães JT; van Spronsen, F.J. ; Borges, Nuno
Association of waist circumference with inflammatory markers in phenylketonuria (2013)
Poster in an International Conference
Rocha, Júlio; Spronsen, F.; Almeida, M.; Silva, N.; Ramos, Elisabete; Borges, Nuno; Guimarães, João

See all (213)

Of the same journal

A Comparison of Active Pharmacovigilance Strategies Used to Monitor Adverse Events to Antiviral Agents: A Systematic Review (2024)
Another Publication in an International Scientific Journal
Ferreira-Da-Silva, R; Reis-Pardal, J; Pinto, M; Monteiro-Soares, M; Sousa-Pinto, B; Morato, M; Polonia, J; Ribeiro-Vaz, I
Workshop- and Telephone-Based Interventions to Improve Adverse Drug Reaction Reporting A Cluster-Randomized Trial in Portugal (2012)
Article in International Scientific Journal
Maria Teresa Herdeiro; Ines Ribeiro Vaz; Monica Ferreira; Jorge Polonia; Amilcar Falcao; Adolfo Figueiras
Promoting Spontaneous Adverse Drug Reaction Reporting in Hospitals Using a Hyperlink to the Online Reporting Form An Ecological Study in Portugal (2012)
Article in International Scientific Journal
Ribeiro Vaz, I; Cristina Costa Santos; Costa-Pereira A; Ricardo Cruz Correia
Promoting Spontaneous Adverse Drug Reaction Reporting in Hospitals Using a Hyperlink to the Online Reporting Form (2012)
Article in International Scientific Journal
Ribeiro-Vaz, I; Cristina Costa Santos; da Costa-Pereira, A; Cruz-Correia, R
Physicians' attitudes and adverse drug reaction reporting - A case-control study in Portugal (2005)
Article in International Scientific Journal
Herdeiro, MT; Figueiras, A; Polonia, J; Gestal Otero, JJ

See all (9)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-25 at 02:20:44 | Privacy Policy | Personal Data Protection Policy | Whistleblowing